<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="187593">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00651573</url>
  </required_header>
  <id_info>
    <org_study_id>08-064</org_study_id>
    <nct_id>NCT00651573</nct_id>
  </id_info>
  <brief_title>Balancing Risk: Red Blood Cell Transfusion Strategies In Cardiac Surgery</brief_title>
  <official_title>Balancing Risk: Red Blood Cell Transfusion Strategies In Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine the best blood level to begin transfusing
      red blood cells in individuals undergoing cardiac surgery.

      The secondary aim is to determine the impact of red cell transfusion on health-related
      quality of life following surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consecutive consenting patients who meet the inclusion criteria will be randomized to one of
      2 transfusion groups based on their HCT value.

      Hematocrit Groups:

        1. 24%

        2. 28%

      Red blood cell transfusion will be given only when hematocrit values fall below the assigned
      group value. When the hematocrit value falls to a value less than the value for the
      randomized group a 1 unit RBC transfusion will be administered. Following administration of
      the 1 unit transfusion a repeat HCT is performed; if the hematocrit value responds to
      transfusion and is greater than or equal to the randomized group no further transfusions
      will be administered. A measurement of the patient's HCT after each unit of RBC administered
      is required prior to administering additional units. If a patient's hematocrit is greater
      than the value for the group which they are randomized, no transfusion of RBC is necessary.
      Other management decisions are left up to the discretion of the care team. Adherence to the
      treatment protocol will be required for the patients in the operating room, intensive care
      unit and postoperatively until discharge from the hospital.

      Before surgery, the patient will be asked to respond to a quality-of-life questionnaire.
      Follow up phone calls will be made by Study personnel at 1 and 3 months after surgery to ask
      the same questions.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2007</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double Blind (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hematocrit values</measure>
    <time_frame>post-induction, first few seconds</time_frame>
    <description>The primary aim is to determine the optimal hematocrit for which transfusion of RBC units is indicated to minimize the detrimental effects of anemia or transfusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hematocrit values</measure>
    <time_frame>every 20 minutes</time_frame>
    <description>The primary aim is to determine the optimal hematocrit for which transfusion of RBC units is indicated to minimize the detrimental effects of anemia or transfusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hematocrit values</measure>
    <time_frame>Post cardiopulmonary bypass, first few seconds</time_frame>
    <description>The primary aim is to determine the optimal hematocrit for which transfusion of RBC units is indicated to minimize the detrimental effects of anemia or transfusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hematocrit values</measure>
    <time_frame>pre-induction, first few seconds</time_frame>
    <description>The primary aim is to determine the optimal hematocrit for which transfusion of RBC units is indicated to minimize the detrimental effects of anemia or transfusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hematocrit values</measure>
    <time_frame>in ICU, daily</time_frame>
    <description>The primary aim is to determine the optimal hematocrit for which transfusion of RBC units is indicated to minimize the detrimental effects of anemia or transfusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>health-related quality of life following surgery.</measure>
    <time_frame>12 weeks after patient's surgery</time_frame>
    <description>The secondary aim is to determine the impact of red cell transfusion on health-related quality of life following surgery.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>Focus- Optimal HCT to Balance Anemia and RBC.</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Red blood cell transfusion will be given when hematocrit values fall below the assigned group 1 value which is 24%. When the hematocrit value falls to less 25%,a 1 unit RBC transfusion will be administered. Following administration of the 1 unit transfusion a repeat HCT is performed; if the hematocrit value responds to transfusion and is greater than or equal to 25%, no further transfusions will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Red blood cell transfusion will be given when hematocrit values fall below the assigned group 1 value which is 28%. When the hematocrit value falls to less 28%,a 1 unit RBC transfusion will be administered. Following administration of the 1 unit transfusion a repeat HCT is performed; if the hematocrit value responds to transfusion and is greater than or equal to 85%, no further transfusions will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood transfusion at hematocrit value less than 25%</intervention_name>
    <description>transfusion</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood transfusion at hematocrit value less than 28%</intervention_name>
    <description>transfusion</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All primary and reoperative adult cardiac surgical patients undergoing
             cardiopulmonary bypass for coronary artery bypass grafting, coronary artery bypass
             grafting with a valve procedure, isolated valve procedures and ascending aortic
             repair for aneurysm or dissection procedures.

        Exclusion Criteria:

          -  Age less than 18 years

          -  Congenital procedures

          -  Emergencies

          -  descending thoracic aortic aneurysm repairs

          -  Left or right ventricular assist devices

          -  Left ventricular aneurysm resections

          -  Heart or lung transplantation

          -  Those unable to receive blood for religious reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel I Sessler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Colleen Koch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jinbo Liu, MD</last_name>
    <phone>216-445-4289</phone>
    <email>liuj6@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gretchen Upton</last_name>
    <phone>216-444-3289</phone>
    <email>uptong@ccf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Koch, MD</last_name>
      <phone>216-445-7418</phone>
      <email>kochc@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Gretchen Upton</last_name>
      <phone>216-905-3932</phone>
      <email>uptong@ccf.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>S.A.L. Hospital and Medical Institute</name>
      <address>
        <city>Ahmedabad</city>
        <state>Thaltej,</state>
        <zip>380054</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anil Jain</last_name>
      <phone>+91-79-4005 4103</phone>
    </contact>
    <contact_backup>
      <last_name>Dhruti Trivedi</last_name>
      <phone>91-79-4005 4103</phone>
      <email>hcaresearch.cvts@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 4, 2013</lastchanged_date>
  <firstreceived_date>March 31, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Colleen Koch, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Surgery</keyword>
  <keyword>Cardiopulmonary bypass</keyword>
  <keyword>Coronary artery bypass graft</keyword>
  <keyword>Valve procedure</keyword>
  <keyword>Hematocrit level</keyword>
  <keyword>Outcomes</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
